Clareo Health | Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Willing and able to provide written informed consent
HCV RNA ≥ 10\^4 IU/mL
HCV genotype 3
Chronic HCV infection (≥ 6 months)
Females of childbearing potential must have a negative serum pregnancy test
Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception
You may not be if
Current or prior history of clinically-significant illness (other than HCV) that may interfere with subject treatment, assessment or compliance with the protocol
Screening ECG with clinically significant abnormalities
Laboratory results outside of acceptable ranges at Screening
Pregnant or nursing female or male with pregnant female partner
Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson's disease, alfa-1 antitrypsin deficiency, cholangitis)
Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)
